Filing Details

Accession Number:
0000914190-21-000185
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-16 19:22:16
Reporting Period:
2021-06-14
Accepted Time:
2021-06-16 19:22:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534980 R. Charles Kummeth 614 Mckinley Place Ne
Minneapolis MN 55413
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-14 7,132 $449.10 167,253 No 4 S Direct
Common Stock Disposition 2021-06-14 349 $450.10 166,904 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100 Indirect By Step-Son
Common Stock 100 Indirect By Step-Daughter
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (Right to Buy) $108.49 2022-08-07 95,346 95,346 Direct
Common Stock Stock Options (Right to Buy) $108.49 2022-08-07 79,517 79,517 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 154,169 154,169 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 102,779 102,779 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 117,342 117,342 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 78,228 78,228 Direct
Common Stock Restricted Stock Units $0.00 16,918 16,918 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 90,334 90,334 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 60,222 60,222 Direct
Common Stock Restricted Stock Units $0.00 16,937 16,937 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 85,725 85,725 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 57,150 57,150 Direct
Common Stock Restricted Stock Units $0.00 12,879 12,879 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 57,442 57,442 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 38,295 38,295 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 16,650 16,650 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 16,650 16,650 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2022-08-07 95,346 95,346 Direct
2022-08-07 79,517 79,517 Direct
2023-08-18 154,169 154,169 Direct
2023-08-18 102,779 102,779 Direct
2024-08-09 117,342 117,342 Direct
2024-08-09 78,228 78,228 Direct
16,918 16,918 Direct
2025-08-08 90,334 90,334 Direct
2025-08-08 60,222 60,222 Direct
16,937 16,937 Direct
2026-08-07 85,725 85,725 Direct
2026-08-07 57,150 57,150 Direct
12,879 12,879 Direct
2027-08-05 57,442 57,442 Direct
2027-08-05 38,295 38,295 Direct
2027-08-05 16,650 16,650 Direct
2027-08-05 16,650 16,650 Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023.
  4. Fully exercisable.
  5. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  6. Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
  7. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  8. Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.
  9. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  10. Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.
  11. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  12. Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
  13. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
  14. Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.